MX2021014855A - {6-[(2-amino-3-cloropiridin-4-il)sulfanil]-3-[(3s,4s)-4-amino-3-m etil-2 oxa-8-azaspiro[4.5]decan-8-il]-5-metilpirazin-2-il}metanol, un inhibidor de shp2. - Google Patents

{6-[(2-amino-3-cloropiridin-4-il)sulfanil]-3-[(3s,4s)-4-amino-3-m etil-2 oxa-8-azaspiro[4.5]decan-8-il]-5-metilpirazin-2-il}metanol, un inhibidor de shp2.

Info

Publication number
MX2021014855A
MX2021014855A MX2021014855A MX2021014855A MX2021014855A MX 2021014855 A MX2021014855 A MX 2021014855A MX 2021014855 A MX2021014855 A MX 2021014855A MX 2021014855 A MX2021014855 A MX 2021014855A MX 2021014855 A MX2021014855 A MX 2021014855A
Authority
MX
Mexico
Prior art keywords
amino
decan
azaspiro
chloropyridin
sulfanyl
Prior art date
Application number
MX2021014855A
Other languages
English (en)
Spanish (es)
Inventor
Shaoling Li
Steven G Ballmer
Original Assignee
Revolution Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revolution Medicines Inc filed Critical Revolution Medicines Inc
Publication of MX2021014855A publication Critical patent/MX2021014855A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2021014855A 2019-06-07 2020-06-04 {6-[(2-amino-3-cloropiridin-4-il)sulfanil]-3-[(3s,4s)-4-amino-3-m etil-2 oxa-8-azaspiro[4.5]decan-8-il]-5-metilpirazin-2-il}metanol, un inhibidor de shp2. MX2021014855A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962858837P 2019-06-07 2019-06-07
PCT/US2020/036137 WO2020247643A1 (en) 2019-06-07 2020-06-04 Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor

Publications (1)

Publication Number Publication Date
MX2021014855A true MX2021014855A (es) 2022-01-18

Family

ID=71787182

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014855A MX2021014855A (es) 2019-06-07 2020-06-04 {6-[(2-amino-3-cloropiridin-4-il)sulfanil]-3-[(3s,4s)-4-amino-3-m etil-2 oxa-8-azaspiro[4.5]decan-8-il]-5-metilpirazin-2-il}metanol, un inhibidor de shp2.

Country Status (15)

Country Link
US (2) US11220501B2 (cg-RX-API-DMAC7.html)
EP (1) EP3980128A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022534788A (cg-RX-API-DMAC7.html)
KR (1) KR20220019017A (cg-RX-API-DMAC7.html)
CN (2) CN114190090A (cg-RX-API-DMAC7.html)
AU (1) AU2020288631A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021022635A2 (cg-RX-API-DMAC7.html)
CA (1) CA3142430A1 (cg-RX-API-DMAC7.html)
IL (1) IL288568A (cg-RX-API-DMAC7.html)
MA (1) MA56113A (cg-RX-API-DMAC7.html)
MX (1) MX2021014855A (cg-RX-API-DMAC7.html)
PH (1) PH12021552902A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112461QA (cg-RX-API-DMAC7.html)
TW (1) TW202112785A (cg-RX-API-DMAC7.html)
WO (1) WO2020247643A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI852912B (zh) 2017-09-07 2024-08-21 美商銳新醫藥公司 Shp2抑制劑組合物以及治療癌症的方法
CA3142430A1 (en) 2019-06-07 2020-12-10 Revolution Medicines, Inc. Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor
TW202313041A (zh) 2021-06-09 2023-04-01 瑞士商諾華公司 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合
TW202317100A (zh) 2021-06-23 2023-05-01 瑞士商諾華公司 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途
US20240374571A1 (en) 2021-09-01 2024-11-14 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
EP1871762A2 (en) * 2005-04-18 2008-01-02 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
NZ623069A (en) 2009-08-17 2015-11-27 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
JO3517B1 (ar) * 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
ES2699351T3 (es) * 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
IL311645B2 (en) 2016-07-12 2025-11-01 Revolution Medicines Inc 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors
TWI852912B (zh) 2017-09-07 2024-08-21 美商銳新醫藥公司 Shp2抑制劑組合物以及治療癌症的方法
KR20200143417A (ko) 2018-04-10 2020-12-23 레볼루션 메디슨즈, 인크. Shp2 억제제 조성물, 암을 치료하는 방법 및 shp2 돌연변이를 갖는 대상체를 확인하는 방법
CA3142430A1 (en) 2019-06-07 2020-12-10 Revolution Medicines, Inc. Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor

Also Published As

Publication number Publication date
MA56113A (fr) 2022-04-13
US12528807B2 (en) 2026-01-20
JP2022534788A (ja) 2022-08-03
TW202112785A (zh) 2021-04-01
CN115141205A (zh) 2022-10-04
EP3980128A1 (en) 2022-04-13
IL288568A (en) 2022-02-01
AU2020288631A1 (en) 2021-12-09
BR112021022635A2 (pt) 2022-01-04
JP2025138706A (ja) 2025-09-25
PH12021552902A1 (en) 2022-04-04
US11220501B2 (en) 2022-01-11
CN114190090A (zh) 2022-03-15
WO2020247643A1 (en) 2020-12-10
KR20220019017A (ko) 2022-02-15
CA3142430A1 (en) 2020-12-10
US20210253574A1 (en) 2021-08-19
SG11202112461QA (en) 2021-12-30
US20220298159A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
PH12021552902A1 (en) Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor
PH12021550045A1 (en) 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
MX2022011534A (es) Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa.
MX2022008066A (es) Compuestos triciclicos sustituidos.
EP4699609A3 (en) Heterocyclic glp-1 agonists
WO2019191092A8 (en) Compounds for treating huntington's disease
WO2020016749A3 (en) Chemical process for preparing phenylpiperidinyl indole derivatives
MX2020009738A (es) Derivados de imidazolidin-2-ona sustituidos como inhibidores de prmt5.
JP2018507890A5 (cg-RX-API-DMAC7.html)
JOP20180092A1 (ar) مثبطات hiv بروتياز
EP4541422A3 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
MX389965B (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos
CA2665931C (en) Hydrobenzamide derivatives as inhibitors of hsp90
ZA202007566B (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
MY209603A (en) Hydroxypyridoxazepines as nrf2 activators
WO2019178191A8 (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors
MX2013000295A (es) Procedimiento de preparacion de un inhibidor especifico de la trombina.
WO2018209363A3 (en) PROPIONIC ACID DERIVATIVES AND ASSOCIATED METHODS OF USE
MX2019013562A (es) Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
PH12022551241A1 (en) Egfr inhibitors
CR20210181A (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
ZA202105887B (en) Selective inhibitor of protein arginine methyltransferase 5 (prmt5)
MY198008A (en) Crystal of benzofuran derivative free base and preparation method
MX2021011374A (es) Compuestos de heteroaril(heterocyclil)metanol útiles en el tratamiento de la hiperglucemia.